查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1776724

數位治療 (DTx) 市場預測至 2032 年：按產品、收益模式、銷售管道、部署模式、應用、最終用戶和地區進行的全球分析

Digital Therapeutics (DTx) Market Forecasts to 2032 - Global Analysis By Product (Software & Services and Devices), Revenue Modal, Sales Channel, Deployment Mode, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球數位治療 (DTx) 市場預計在 2025 年達到 103 億美元，到 2032 年將達到 499 億美元，預測期內的複合年成長率為 25.2%。

Digital Therapeutics (DTx) 是經臨床評估的實證軟體程序，旨在治療、管理或預防各種疾病。 Digital Therapeutics 使用智慧型手機和平板電腦等設備直接向患者提供治療性介入，通常作為傳統療法的補充。與一般健康應用程式不同，DTx 經過嚴格的臨床試驗和監管審查，以確保安全性和有效性。 DTx 可以治療各種疾病，從糖尿病、失眠到焦慮和過動症。透過結合個人化回饋、數據追蹤和行為科學，DTx 幫助個人掌控自身健康並改善臨床療效。

根據世界衛生組織（WHO）的數據，2019年，超過10億高血壓患者（佔全球高血壓患者的82%）生活在中低收入國家。

慢性病盛行率上升

糖尿病、心血管疾病和呼吸系統疾病等慢性疾病的盛行率不斷上升，是數位治療 (DTx) 市場的主要驅動力。隨著這些長期疾病對全球帶來的負擔日益加重，對可擴展、個人化且經濟高效的照護解決方案的需求也日益成長。 DTx 平台提供持續監測、行為矯正和提升病人參與，進而改善治療效果。主動和遠距疾病管理的轉變正在推動整個醫療保健系統的採用，使 DTx 成為現代慢性病照護模式的重要組成部分。

資料隱私和網路安全問題

對資料隱私和網路安全的擔憂正在阻礙數位治療 (DTx) 市場的成長。由於 DTx 平台處理敏感的醫療訊息，其易受資料外洩和未授權存取的影響，引發了嚴重的信任和合規性問題。這些風險阻礙了患者的採用，並減緩了醫療服務提供者的整合。 HIPAA 和 GDPR 等日益嚴格的法規也增加了開發的複雜性和成本，使得安全和可擴展的部署成為全球 DTx 公司持續面臨的挑戰。

向預防性醫療保健的轉變

全球向預防性醫療保健的轉變正在推動數位治療 (DTx) 市場的強勁成長。由於醫療保健系統優先考慮早期療育和健康而非被動治療，DTx 解決方案提供個人化的生活方式管理、風險降低和長期疾病預防方案。這些工具使患者能夠透過即時回饋、行為指導和數位互動來掌控自己的健康。這種模式轉移正在推動對 DTx 平台的需求，使其成為全球現代、經濟高效的預防性醫療保健策略的重要組成部分。

開發和維護成本高

高昂的開發和維護成本是數位治療 (DTx) 市場成長的主要障礙。創建經臨床檢驗且符合法規要求的 DTx 解決方案需要在研究、設計和持續更新方面投入大量資金。中小企業通常面臨資源限制，限制了創新和市場准入。此外，持續的技術支援和平台安全需求也增加了營運成本，使得在成本敏感的醫療保健環境中難以實現擴充性和普及性。

COVID-19的影響

新冠疫情加速了數位療法 (DTx) 的普及，因為封鎖和保持社交距離凸顯了遠距醫療解決方案的需求。由於面對面就診受限，患者和醫療服務提供者紛紛轉向數位平台進行慢性病管理、心理健康支援和預防保健。遠端醫療的普及激增，提升了 DTx 的認知和整合度，鞏固了其作為後疫情時代醫療生態系統中具有韌性和可擴展性的解決方案的地位。

戒菸市場預計將成為預測期內最大的市場

由於人們日益意識到吸菸帶來的健康風險，預計戒菸領域將在預測期內佔據最大的市場佔有率。 DTx平台提供基於證據的可擴展干預措施，包括認知行為療法、數位輔導和個人化追蹤，以幫助個人有效戒菸。這些技術驅動的方法提供了便捷的非侵入性支持，可提高戒菸成功率和長期戒菸效果。隨著社會和臨床對戒菸工具的需求不斷成長，DTx解決方案正逐漸成為行為健康管理的重要組成部分。

糖尿病領域預計在預測期內實現最高複合年成長率

由於全球第1型和第2型糖尿病的盛行率不斷上升，預計糖尿病領域將在預測期內達到最高成長率。 DTx解決方案提供有效的自我管理工具，包括血糖監測、飲食建議和數位指導，幫助患者更好地控制病情。這種個人化、數據主導的介入措施可以提高患者服藥順從性，並改善臨床療效。隨著醫療保健系統尋求經濟高效的慢性病治療方案，對數位化糖尿病管理的需求正在穩步推動DTx市場的擴張。

比最大的地區

在預測期內，亞太地區預計將佔據最大的市場佔有率，這得益於快速的數位轉型、慢性病盛行率的上升以及智慧型手機普及率的提高。各國政府和醫療機構正在採用 DTx，以增強偏遠地區的醫療服務，並減輕系統負擔。印度、中國和日本等國家憑藉其精通技術的人口和不斷擴張的醫療基礎設施，在 DTx 應用方面處於領先地位。這種有利的環境正在推動創新和投資，使亞太地區成為下一代以患者為中心的數位醫療解決方案的活力中心。

複合年成長率最高的地區：

由於先進的醫療基礎設施、較高的數位素養以及有利的監管支持，北美地區預計將在預測期內實現最高的複合年成長率。該地區正在積極採用技術賦能的醫療保健，尤其是在慢性病管理領域，這使得遠距醫療 (DTx) 成為現代醫學的基石。策略性投資、不斷擴大的保險覆蓋範圍以及強力的臨床檢驗進一步推動了市場發展勢頭。隨著個人化遠距照護解決方案需求的不斷成長，北美地區將繼續在各個治療領域的遠距醫療創新與整合方面引領產業發展。

免費客製化服務：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球數位治療 (DTx) 市場（按產品）

  • 軟體和服務
  • 裝置

6. 全球數位治療 (DTx) 市場按收益模式分類

  • 訂閱
  • 一次性購買/許可
  • 基於結果/價值

7. 全球數位治療 (DTx) 市場按銷售管道

  • 企業對企業（B2B）
  • 企業對消費者（B2C）

8. 全球數位治療 (DTx) 市場（按部署模式）

  • 本地
  • 雲端基礎

9. 全球數位治療 (DTx) 市場（按應用）

  • 糖尿病
  • 肥胖
  • 心血管疾病
  • 呼吸系統疾病
  • 中樞神經系統 (CNS) 疾病
  • 禁止抽煙
  • 胃腸道疾病
  • 其他用途

第 10 章：全球數位治療 (DTx) 市場（按最終用戶分類）

  • 病人
  • 提供者
  • 付款人
  • 雇主
  • 其他最終用戶

第 11 章：全球數位治療 (DTx) 市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司概況

  • Pear Therapeutics, Inc.
  • Omada Health, Inc.
  • Livongo Health, Inc.
  • Propeller Health
  • Akili Interactive Labs, Inc.
  • Better Therapeutics, Inc.
  • Voluntis, Inc.
  • Kaia Health
  • Happify Health
  • WellDoc, Inc.
  • Cognoa, Inc.
  • Click Therapeutics, Inc.
  • Big Health
  • Canary Health
  • Biofourmis
  • Lark Health
  • 2Morrow, Inc.
  • DarioHealth Corp.
  • MindMaze
  • SilverCloud Health
Product Code: SMRC30055

According to Stratistics MRC, the Global Digital Therapeutics (DTx) Market is accounted for $10.3 billion in 2025 and is expected to reach $49.9 billion by 2032 growing at a CAGR of 25.2% during the forecast period. Digital Therapeutics (DTx) is evidence-based, clinically evaluated software programs designed to treat, manage, or prevent medical disorders and diseases. They deliver therapeutic interventions directly to patients using devices like smartphones or tablets, often supplementing traditional treatments. Unlike general wellness apps, DTx undergo rigorous clinical trials and regulatory review to ensure safety and efficacy. They can address a wide range of conditions, from diabetes and insomnia to anxiety and ADHD. By combining personalized feedback, data tracking, and behavioral science, DTx empower individuals to take control of their health and improve clinical outcomes-all without relying solely on medication or in-person care.

According to World Health Organization (WHO), in 2019, over one billion people with hypertension (82% of all people with hypertension worldwide) lived in low and middle-income countries.

Market Dynamics:

Driver:

Rising Prevalence of Chronic Diseases

The rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and respiratory conditions is significantly propelling the Digital Therapeutics (DTx) market. As the global burden of these long-term conditions increases, there is growing demand for scalable, personalized, and cost-effective care solutions. DTx platforms offer continuous monitoring, behavior modification, and improved patient engagement, enhancing treatment outcomes. This shift toward proactive and remote disease management is driving adoption across healthcare systems, making DTx an essential component in modern chronic care models.

Restraint:

Data Privacy & Cybersecurity Concerns

Concerns over data privacy and cybersecurity are hampering the growth of the Digital Therapeutics (DTx) market. As DTx platforms handle sensitive health information, vulnerabilities to data breaches and unauthorized access raise serious trust and compliance issues. These risks deter patient adoption and slow provider integration. Stricter regulations like HIPAA and GDPR also increase the complexity and cost of development, making secure, scalable deployment a persistent challenge for DTx companies worldwide.

Opportunity:

Shift toward Preventive Healthcare

The global shift toward preventive healthcare is fueling robust growth in the Digital Therapeutics (DTx) market. As healthcare systems prioritize early intervention and wellness over reactive treatment, DTx solutions offer personalized programs for lifestyle management, risk reduction, and long-term disease prevention. These tools empower patients to take control of their health through real-time feedback, behavior coaching, and digital engagement. This paradigm shift is increasing demand for DTx platforms, positioning them as integral to modern, and cost-effective preventive care strategies worldwide.

Threat:

High Development & Maintenance Costs

High development and maintenance costs pose a significant barrier to the growth of the Digital Therapeutics (DTx) market. Creating clinically validated, regulatory-compliant DTx solutions requires substantial investment in research, design, and ongoing updates. Smaller companies often struggle with resource constraints, limiting innovation and market entry. Additionally, the need for continuous technical support and platform security increases operational expenses, making scalability and widespread adoption more challenging in cost-sensitive healthcare environments.

Covid-19 Impact

The COVID-19 pandemic accelerated the adoption of Digital Therapeutics (DTx) as lockdowns and social distancing highlighted the need for remote healthcare solutions. With in-person visits limited, patients and providers turned to digital platforms for chronic disease management, mental health support, and preventive care. This surge in telehealth acceptance boosted awareness and integration of DTx, solidifying its role as a resilient, scalable solution in post-pandemic healthcare ecosystems.

The smoking cessation segment is expected to be the largest during the forecast period

The smoking cessation segment is expected to account for the largest market share during the forecast period, due to rising awareness of smoking-related health risks. DTx platforms offer evidence-based, scalable interventions-like cognitive behavioral therapy, digital coaching, and personalized tracking-to help individuals quit smoking effectively. These tech-enabled approaches provide accessible, non-invasive support that enhances success rates and long-term abstinence. As public and clinical demand for smoking cessation tools grows, DTx solutions are gaining prominence as vital components in behavioral health management.

The diabetes segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the diabetes segment is predicted to witness the highest growth rate, due to increasing global prevalence of Type 1 and Type 2 diabetes. DTx solutions offer effective self-management tools, including glucose monitoring, dietary guidance, and digital coaching, empowering patients to better control their condition. These personalized, data-driven interventions enhance adherence and improve clinical outcomes. As healthcare systems seek cost-efficient chronic care solutions, the demand for digital diabetes management is steadily fueling expansion across the DTx landscape.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to rapid digital transformation, rising chronic disease prevalence, and increasing smartphone penetration. Governments and healthcare providers are embracing DTx to enhance remote care access and reduce system burdens. With tech-savvy populations and expanding healthcare infrastructure, countries like India, China, and Japan are leading adoption. This favorable environment is driving innovation and investment, positioning Asia Pacific as a dynamic hub for next-generation, patient-centered digital healthcare solutions.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to advanced healthcare infrastructure, high digital literacy, and favorable regulatory support. The region's proactive adoption of tech-enabled healthcare, especially in managing chronic conditions, positions DTx as a cornerstone of modern medical care. Strategic investments, insurance coverage expansion, and strong clinical validation further boost market momentum. With increasing demand for personalized and remote care solutions, North America continues to lead innovation and integration of DTx across diverse therapeutic areas.

Key players in the market

Some of the key players profiled in the Digital Therapeutics (DTx) Market include Pear Therapeutics, Inc., Omada Health, Inc., Livongo Health, Inc., Propeller Health, Akili Interactive Labs, Inc., Better Therapeutics, Inc., Voluntis, Inc., Kaia Health, Happify Health, WellDoc, Inc., Cognoa, Inc., Click Therapeutics, Inc., Big Health, Canary Health, Biofourmis, Lark Health, 2Morrow, Inc., DarioHealth Corp., MindMaze and SilverCloud Health.

Key Developments:

In June 2022, Happify Health, in collaboration with Almirall, launched Claro, a digital wellness program for individuals living with psoriasis in the UK, Spain, and Italy. Designed to tackle the common mental health challenges associated with the condition affecting 20-30% of moderate-to-severe patients-Claro integrates cognitive behavioral therapy, positive psychology, and mindfulness to boost emotional resilience and quality of life.

In August 2021, Happify Health and Higi have joined forces to deliver AI-powered, digitally personalized healthcare through Higi's expansive network of over 10,000 Smart Health Stations located in US retail outlets, including pharmacies and grocery stores.

Products Covered:

  • Software & Services
  • Devices

Revenue Modals Covered:

  • Subscription
  • One time Purchase/Licensing
  • Outcome/Value based

Sales Channels Covered:

  • Business-to-Business (B2B)
  • Business-to-Consumer (B2C)

Deployment Modes Covered:

  • On-Premises
  • Cloud-Based

Applications Covered:

  • Diabetes
  • Obesity
  • Cardiovascular Diseases
  • Respiratory Diseases
  • Central Nervous System (CNS) Disorders
  • Smoking Cessation
  • Gastrointestinal Disorders
  • Other Applications

End Users Covered:

  • Patients
  • Providers
  • Payers
  • Employers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Digital Therapeutics (DTx) Market, By Product

  • 5.1 Introduction
  • 5.2 Software & Services
  • 5.3 Devices

6 Global Digital Therapeutics (DTx) Market, By Revenue Modal

  • 6.1 Introduction
  • 6.2 Subscription
  • 6.3 One time Purchase/Licensing
  • 6.4 Outcome/Value based

7 Global Digital Therapeutics (DTx) Market, By Sales Channel

  • 7.1 Introduction
  • 7.2 Business-to-Business (B2B)
  • 7.3 Business-to-Consumer (B2C)

8 Global Digital Therapeutics (DTx) Market, By Deployment Mode

  • 8.1 Introduction
  • 8.2 On-Premises
  • 8.3 Cloud-Based

9 Global Digital Therapeutics (DTx) Market, By Application

  • 9.1 Introduction
  • 9.2 Diabetes
  • 9.3 Obesity
  • 9.4 Cardiovascular Diseases
  • 9.5 Respiratory Diseases
  • 9.6 Central Nervous System (CNS) Disorders
  • 9.7 Smoking Cessation
  • 9.8 Gastrointestinal Disorders
  • 9.9 Other Applications

10 Global Digital Therapeutics (DTx) Market, By End User

  • 10.1 Introduction
  • 10.2 Patients
  • 10.3 Providers
  • 10.4 Payers
  • 10.5 Employers
  • 10.6 Other End Users

11 Global Digital Therapeutics (DTx) Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Pear Therapeutics, Inc.
  • 13.2 Omada Health, Inc.
  • 13.3 Livongo Health, Inc.
  • 13.4 Propeller Health
  • 13.5 Akili Interactive Labs, Inc.
  • 13.6 Better Therapeutics, Inc.
  • 13.7 Voluntis, Inc.
  • 13.8 Kaia Health
  • 13.9 Happify Health
  • 13.10 WellDoc, Inc.
  • 13.11 Cognoa, Inc.
  • 13.12 Click Therapeutics, Inc.
  • 13.13 Big Health
  • 13.14 Canary Health
  • 13.15 Biofourmis
  • 13.16 Lark Health
  • 13.17 2Morrow, Inc.
  • 13.18 DarioHealth Corp.
  • 13.19 MindMaze
  • 13.20 SilverCloud Health

List of Tables

  • Table 1 Global Digital Therapeutics (DTx) Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Digital Therapeutics (DTx) Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Digital Therapeutics (DTx) Market Outlook, By Software & Services (2024-2032) ($MN)
  • Table 4 Global Digital Therapeutics (DTx) Market Outlook, By Devices (2024-2032) ($MN)
  • Table 5 Global Digital Therapeutics (DTx) Market Outlook, By Revenue Modal (2024-2032) ($MN)
  • Table 6 Global Digital Therapeutics (DTx) Market Outlook, By Subscription (2024-2032) ($MN)
  • Table 7 Global Digital Therapeutics (DTx) Market Outlook, By One time Purchase/Licensing (2024-2032) ($MN)
  • Table 8 Global Digital Therapeutics (DTx) Market Outlook, By Outcome/Value based (2024-2032) ($MN)
  • Table 9 Global Digital Therapeutics (DTx) Market Outlook, By Sales Channel (2024-2032) ($MN)
  • Table 10 Global Digital Therapeutics (DTx) Market Outlook, By Business-to-Business (B2B) (2024-2032) ($MN)
  • Table 11 Global Digital Therapeutics (DTx) Market Outlook, By Business-to-Consumer (B2C) (2024-2032) ($MN)
  • Table 12 Global Digital Therapeutics (DTx) Market Outlook, By Deployment Mode (2024-2032) ($MN)
  • Table 13 Global Digital Therapeutics (DTx) Market Outlook, By On-Premises (2024-2032) ($MN)
  • Table 14 Global Digital Therapeutics (DTx) Market Outlook, By Cloud-Based (2024-2032) ($MN)
  • Table 15 Global Digital Therapeutics (DTx) Market Outlook, By Application (2024-2032) ($MN)
  • Table 16 Global Digital Therapeutics (DTx) Market Outlook, By Diabetes (2024-2032) ($MN)
  • Table 17 Global Digital Therapeutics (DTx) Market Outlook, By Obesity (2024-2032) ($MN)
  • Table 18 Global Digital Therapeutics (DTx) Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
  • Table 19 Global Digital Therapeutics (DTx) Market Outlook, By Respiratory Diseases (2024-2032) ($MN)
  • Table 20 Global Digital Therapeutics (DTx) Market Outlook, By Central Nervous System (CNS) Disorders (2024-2032) ($MN)
  • Table 21 Global Digital Therapeutics (DTx) Market Outlook, By Smoking Cessation (2024-2032) ($MN)
  • Table 22 Global Digital Therapeutics (DTx) Market Outlook, By Gastrointestinal Disorders (2024-2032) ($MN)
  • Table 23 Global Digital Therapeutics (DTx) Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 24 Global Digital Therapeutics (DTx) Market Outlook, By End User (2024-2032) ($MN)
  • Table 25 Global Digital Therapeutics (DTx) Market Outlook, By Patients (2024-2032) ($MN)
  • Table 26 Global Digital Therapeutics (DTx) Market Outlook, By Providers (2024-2032) ($MN)
  • Table 27 Global Digital Therapeutics (DTx) Market Outlook, By Payers (2024-2032) ($MN)
  • Table 28 Global Digital Therapeutics (DTx) Market Outlook, By Employers (2024-2032) ($MN)
  • Table 29 Global Digital Therapeutics (DTx) Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.